Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.48 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28444855 | 0.91 | GPR119 (0.55) | GPR119USP30DPP4HRH3 | |
| SCHEMBL28444854 | 0.91 | GPR119 (0.55) | GPR119USP30DPP4HRH3 | |
| SCHEMBL20165784 | 0.87 | GPR119 (0.49) | GPR119USP30DPP4NR1H2HDAC1 | |
| SCHEMBL27105204 | 0.85 | GPR119 (0.47) | GPR119USP30DPP4NR1H2HDAC1 | |
| SCHEMBL22265869 | 0.83 | USP30 (0.46) | GPR119USP30NR1H2HDAC1HDAC2 | |
| SCHEMBL2283032 | 0.82 | USP30 (0.42) | GPR119USP30 | |
| SCHEMBL31312460 | 0.82 | GPR119 (0.55) | GPR119USP30DPP4HRH3 | |
| SCHEMBL22266021 | 0.82 | GPR119 (0.55) | GPR119USP30DPP4HRH3 | |
| SCHEMBL26394056 | 0.81 | GPR119 (0.45) | GPR119USP30DPP4 | |
| SCHEMBL20912819 | 0.81 | RIPK1 (0.36) | GPR119USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3760623-B1 | TETRAHYDRO-PYRIDO[3,4-B]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2026-03-18 | — | — | EP | disclosed |
| US-20250114338-A1 | TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| US-12233052-B2 | Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof | GENENTECH, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| CN-118005631-A | Tetrahydro-pyrido [3,4-b ] indole estrogen receptor modulators and uses thereof | 豪夫迈·罗氏有限公司 | 2024-05-10 | — | — | CN | disclosed |
| CN-117865872-A | Tetrahydro-pyrido [3,4-b ] indole estrogen receptor modulators and uses thereof | 豪夫迈·罗氏有限公司 | 2024-04-12 | — | — | CN | disclosed |
| CN-115667275-B | Boron-containing compounds and uses thereof | 南京再明医药有限公司 | 2024-02-23 | — | — | CN | disclosed |
| CN-112375078-B | Tetrahydro-pyrido [3,4-b ] indole estrogen receptor modulators and uses thereof | 豪夫迈·罗氏有限公司 | 2023-12-19 | — | — | CN | disclosed |
| US-20230045776-A9 | TETRAHYDRO- PYRIDO[3,4- b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2023-02-09 | — | — | US | disclosed |
| US-20230045776-A9 | TETRAHYDRO- PYRIDO[3,4- b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2023-02-09 | — | — | US | disclosed |
| CN-115667275-A | Boron-containing compounds and their use | 先声药业有限公司 | 2023-01-31 | — | — | CN | disclosed |
| US-20170320871-A1 | TETRAHYDROISOQUINOLINE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-09 | — | — | US | disclosed |
| US-20170320871-A1 | TETRAHYDROISOQUINOLINE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-09 | — | — | US | disclosed |
| US-20170320871-A1 | TETRAHYDROISOQUINOLINE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-09 | — | — | US | disclosed |
| EP-3233852-A1 | TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | F. Hoffmann-La Roche AG (CH) | 2017-10-25 | — | — | EP | disclosed |
| WO-2017174757-A1 | TETRAHYDROISOQUINOLINE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2017-10-12 | — | — | WO | disclosed |
| US-20160175289-A1 | TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-06-23 | — | — | US | disclosed |
| WO-2016097072-A1 | TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2016-06-23 | — | — | WO | disclosed |
| US-20160175289-A1 | TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-06-23 | — | — | US | disclosed |
| US-20160175289-A1 | TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-06-23 | — | — | US | disclosed |
| WO-2016097072-A1 | TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12233052-B2 | Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof | ESR2, GPER1, ESR1 | GPR119 114/4885USP30 2757/4885DPP4 1975/4885 |
| US-20250114338-A1 | TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, GPER1, ESR1 | GPR119 114/4885USP30 2757/4885DPP4 1975/4885 |
| US-20160175289-A1 | TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, GPER1, ESR1 | GPR119 114/4885USP30 2757/4885DPP4 1975/4885 |
| US-20170320871-A1 | TETRAHYDROISOQUINOLINE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GPER1, ESR2, ESR1 | GPR119 147/4885USP30 1300/4885DPP4 3287/4885 |
| US-20230045776-A9 | TETRAHYDRO- PYRIDO[3,4- b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, GPER1, ESR1 | GPR119 114/4885USP30 2757/4885DPP4 1975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.